ADHD Therapeutics (MCP-6195) - Global Industry Analysts, Inc.

Research Abstract

This report analyzes the worldwide markets for ADHD Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US and Rest of World. Annual estimates and forecasts are provided for each region for the period of 2006 through 2015. The report profiles 27 companies including many key and niche players such as Eli Lilly & Company, Johnson & Johnson, Janssen-Cilag, Novartis AG, Shire Plc, and UCB S.A. Companies with Drugs in Pipeline for ADHD also discussed in the report include - Abbott Laboratories, Inc., Cortex Pharmaceuticals, Inc., KemPharm, Inc., and NeuroSearch A/S. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Code :	MCP-6195
Price :	$3950
Companies :	27

Pages :	321
Date :	June 2010
Market Data Tables :	103

Complimentary Market Brief:

Request a Complimentary Copy of the Report Insights, Key Findings, Drivers, Trends, Program Sources, and Methodology.

ADHD THERAPEUTICS (Complete Report)

Pages : 321

$3950

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITION

$295

Study Reliability and Reporting Limitations.....I-1

Disclaimers.....I-2

Data Interpretation & Reporting Level.....I-3

Quantitative Techniques & Analytics.....I-3

Product Definitions and Scope of Study.....I-3

II. EXECUTIVE SUMMARY

$2250

1. INDUSTRY OVERVIEW.....II-1

$595

A Prelude.....II-1

Lack of Awareness – A Major Impediment.....II-1

$140

Adult ADHD – A Growing Market Opportunity.....II-2

Table 1: Market Share of ADHD Prescriptions by Age Category: Children, Adolescents and Adults (includes corresponding Graph/Chart).....II-2

$300

Unfulfilled Needs Provide Impetus to Develop New Molecules.....II-3

Safety Concerns Foster Research in Non Stimulant Segment.....II-3

Presence of Co-morbidities with ADHD Creates Opportunities for Combination

Therapies.....II-3

Introduction of Generics Shakes Market.....II-3

$140

Patent Expiries of Major Drugs in the ADHD Market.....II-4

$140

2. COMPETITIVE SCENARIO.....II-5

$495

Table 2: Leading Brands in the Global ADHD Market by Prescription Share (2008) (includes corresponding Graph/Chart).....II-5

Shire Leads the Way.....II-5

$300

J&J’s Concerta – Leading Drug for ADHD by Default.....II-6

Eli Lilly’s Strattera – Creating a Niche.....II-6

$140

Novartis Retains Market Share.....II-7

Pipeline Drugs.....II-7

$140

3. THE ADHD CONUNDRUM.....II-8

$395

ADHD – A Disorder or Marketing Gimmick of Pharmaceutical Companies?.....II-8

Lack of Clear Guidelines and Criteria for Adult Diagnosis Hampers Market.....II-8

$140

Differences in Diagnostic Criteria in Europe and US.....II-9

Hiccups in the Way.....II-9

ADHD in Women.....II-9

$280

4. ADHD – AN INSIGHT.....II-11

$595

Attention Deficit Hyperactivity Disorder (ADHD) – Introduction.....II-11

Brief History of the Disorder.....II-11

$140

Common Co-Occurring Disorders With ADHD.....II-12

Consequences of ADHD.....II-12

What Leads to ADHD?.....II-12

Study Reveals Deficits in Protein Levels in Brain’s Reward/Motivation System.....II-12

$140

ADHD Symptoms.....II-13

DSM IV Criteria for Diagnosis of ADHD.....II-13

DSM IV Criteria for Inattention and Hyperactivity/ Impulsivity.....II-13

$140

Types of ADHD.....II-14

Treating ADHD.....II-14

Stimulants.....II-14

Non-stimulants.....II-14

Others.....II-14

$280

5. REVIEW OF SELECT DRUGS.....II-16

$1450

ADHD Drugs – Background.....II-16

Brand Review.....II-16

Ritalin LA.....II-16

Focalin.....II-16

Table 3: Global Revenues of Novartis’ ADHD Drugs - Ritalin/Focalin (2008-2009) (in US$ million).....II-16

$300

Concerta.....II-17

Table 4: Global Revenues of Concerta (2006-2009) (includes corresponding Graph/Chart).....II-17

Strattera.....II-17

Table 5: Global Revenues of Strattera (2006-2009) (in US$ million) (includes corresponding Graph/Chart).....II-17

$300

Metadate CD.....II-18

Table 6: Global Revenues of Metadate CD/Equasym (2007-2008) (in €Million).....II-18

Adderall XR.....II-18

Table 7: Global Revenues of Adderall XR (2006-2009) (in US$ million) (includes corresponding Graph/Chart).....II-18

$300

Daytrana.....II-19

Table 8: Global Revenues of Daytrana (2006-2009) (in US$ million) (includes corresponding Graph/Chart).....II-19

Vyvanse.....II-19

$300

Table 9: Global Revenues of Vyvanse (2007-2009) (in US$ million) (includes corresponding Graph/Chart).....II-20

Intuniv.....II-20

$600

6. RESEARCH PIPELINE.....II-22

$495

Research Pipeline.....II-22

$140

Supernus Pharmaceuticals’ SPN 810 Proves Successful in Phase IIa Clinical

Trials.....II-23

KemPharm Announces Completion of Phase I Trials of KP106.....II-23

Shire Announces Results of Phase IIIb Clinical Trials of Daytrana® in

Adolescents.....II-23

$140

Addrenex and Sciele Pharma Submit sNDA for Clonicel for ADHD Treatment.....II-24

Targacept Collaborates with AstraZeneca for AZD3480 Clinical Trials.....II-24

Neptune Technologies Announces Positive Reports on Pre-Clinical Trials of Medical Food

Candidate for Treatment of ADHD.....II-24

NeuroSearch Completes Phase II Studies on Efficacy and Security of ABT-894 in Adults

with ADHD.....II-24

$140

Abbott Announces Positive Results From Phase II Studies of a Novel Approach of Treating

ADHD.....II-25

$140

7. PRODUCT LAUNCHES/INTRODUCTIONS.....II-26

Shire Unveils First Prodrug Therapy for ADHD in Canadian Market.....II-26

Teva Launches First Authorized Generic Version of Adderall XR® Capsules.....II-26

Shire Introduces INTUNIV™.....II-26

Eli Lilly Japan Introduces Strattera in the Country.....II-26

$140

8. RECENT INDUSTRY ACTIVITY.....II-27

$595

Avacta Group Acquires TheraGenetics.....II-27

AstraZeneca Grants Interim Payment to Targacept.....II-27

Addrenex Pharmaceuticals Inks Agreement with Dream Pharma.....II-27

Durect Signs Agreement with Orient Pharma.....II-27

$140

Hisamitsu Pharmaceutical Acquires Noven Pharmaceutical.....II-28

Shire Receives FDA Approval for INTUNIV Tablets.....II-28

Shire Pharmaceuticals and GSK Sign a Co-Promotion Deal for Vyvanse.....II-28

Shire Pharmaceuticals Establishes Office in Tokyo.....II-28

$140

Shire and UCB Enter into Agreement.....II-29

Shire Retains Exclusivity for Vyvanse.....II-29

Shire Settles Litigation with Sandoz for Generic Adderall.....II-29

Sciele Pharma to Takeover Addrenex Pharmaceuticals.....II-29

$140

Auriga Laboratories Receives Approval from FDA for LiquaddTM.....II-30

Concerta Extended Release Tablets Receive US FDA Approval for Use in Adult

Treatment.....II-30

Eurand Enters into Settlement with UCB.....II-30

Paladin Labs Secures Dexedrine's Distribution Rights from GlaxoSmithKline.....II-30

$140

Shire Receives Approval from FDA for Use of Vyvanse in Adults.....II-31

Strattera Receives FDA Approval for Maintenance of ADHD in Children &

Adolescents.....II-31

The Dore Group Providing Alternate ADHD Treatment to Drugs Goes Into

Liquidation.....II-31

Shire Takes Over New River Pharmaceuticals to Gain Full Control Over Vyvanse™.....II-31

$140

9. FOCUS ON SELECT PLAYERS.....II-32

$495

Eli Lilly & Company (USA).....II-32

Johnson & Johnson (USA).....II-32

Janssen-Cilag (Switzerland).....II-32

$140

Novartis AG (Switzerland).....II-33

Shire Plc (The UK).....II-33

$140

UCB S.A. (Belgium).....II-34

Companies with Drugs in Pipeline for ADHD.....II-34

Abbott Laboratories, Inc. (USA).....II-34

Cortex Pharmaceuticals, Inc. (US).....II-34

$140

KemPharm, Inc. (USA).....II-35

NeuroSearch A/S (Denmark).....II-35

$140

10. GLOBAL MARKET PERSPECTIVE.....II-36

Table 10: World Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) by Geographic Region – US and Rest of World Markets Independently Analyzed with Annual Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-36

Table 11: World 10 -Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Market by Geographic Region – Percentage Breakdown of Revenues for US and Rest of World Markets for Years 2006, 2009 and 2015.....II-36

$300

III. MARKET

$1950

1. THE UNITED STATES.....III-1

$950

A. Market Analysis.....III-1

Current and Future Analysis.....III-1

ADHD Epidemic in the US !.....III-1

Table 12: Prevalence Rate of ADHD in Different Backgrounds According to Age, Ethnicity, Gender and Family Structure in the US in 2007.....III-1

$150

Causes for Widespread ADHD Diagnosis and Treatment in the US.....III-2

ADHD Drugs Combat Safety Concerns.....III-2

Market Exhibits Greater Potential.....III-2

Table 13: Percentage Share of ADHD Prescriptions in US by Patient Category - Children, Adolescents and Adults (2002 and 2007) (includes corresponding Graph/Chart).....III-2

$150

Lack of Clear Guidelines and Criteria for Adult Diagnosis Hampers Market.....III-3

Cyclical Nature of ADHD Market.....III-3

Competitive Scenario.....III-3

$120

Table 14: Leading Players and Drug Brands in the US ADHD Market (2007, 2008) : Percentage Breakdown of Prescriptions for Shire, McNeil Janssen, Eli Lilly, Novartis, Celltech, Pharmaceuticals / UCB, and Others (includes corresponding Graph/Chart).....III-4

Product Launches.....III-4

$150

Strategic Corporate Developments.....III-5

$360

Select Players.....III-8

$240

B. Market Analytics.....III-10

Table 15: US Recent Past, Current & Future Analysis for Sales Force Automation (SFA) Market Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-10

$150

2. REST OF WORLD.....III-11

$950

A. Market Analysis.....III-11

Current and Future Analysis.....III-11

Review of Select Markets.....III-11

Canada.....III-11

Concerta Leads the Market.....III-11

Table 16: Leading Drug Brands in the Canadian ADHD Market (2008): Percentage Share Breakdown of Revenues for Concerta, Adderall, Dexedrine, Generics, and Others (includes corresponding Graph/Chart).....III-11

$150

Europe.....III-12

Germany.....III-12

Table 17: Prevalence Rates of ADHD in Germany in Terms of Gender, Age and Socioeconomic Status Reimbursement Policy.....III-12

The United Kingdom.....III-12

$150

Australia.....III-13

Product Launches.....III-13

Strategic Corporate Developments.....III-13

$360

Select Players.....III-16

$240

B. Market Analytics.....III-18

Table 18: Rest of World Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Drugs Analyzed with Annual Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-18

$150

IV. COMPETITIVE LANDSCAPE

255

$995

Total Companies Profiled: 27 (including Divisions/Subsidiaries - 33)
Region/Country                 Players

The United States                 20   
Japan                              2
Europe                             9
     Germany                       1
     The United Kingdom            4
     Rest of Europe                4
Asia-Pacific (Excluding Japan)     1
Middle-East                        1

Click here to request a full table of contents and more details on this project.

ADHD THERAPEUTICS - A GLOBAL STRATEGIC BUSINESS REPORT

Research Abstract

Complimentary Market Brief:

TABLE OF CONTENTS

ADHD THERAPEUTICS - A GLOBAL STRATEGIC BUSINESS REPORT stLight.options({ publisher:'12345' });

Research Abstract

Complimentary Market Brief:

TABLE OF CONTENTS

ADHD THERAPEUTICS - A GLOBAL STRATEGIC BUSINESS REPORT